Trial Profile
A clinical study of Ruxolitinib (RUX) for myelofibrosis (MF)-related splenomegaly
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 04 Dec 2018 Results (n=199 patients with early and overt primary Myelofibrosis ) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 27 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association